TNF Pharmaceuticals Partners with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Disease
Reuters
Jun 24
TNF Pharmaceuticals Partners with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Disease
TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has announced a new philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use (Expanded Access) study of their lead candidate, isomyosamine. This study will evaluate isomyosamine as a potential treatment for the rare pediatric autoinflammatory disease, DADA2 (Deficiency of Adenosine Deaminase 2). Isomyosamine is a novel small molecule TNF-alpha inhibitor that offers an orally administered alternative to standard-of-care biological treatments for DADA2, with the advantage of minimal or no immunosuppression. The study aims to assess its effectiveness in addressing the hyperinflammatory and vasculitic aspects of DADA2, a condition primarily affecting children. The results of this study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624517572) on June 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.